Biomedical Engineering Reference
In-Depth Information
417. Chu XY, Kato Y, Sugiyama Y. 1997. Multiplicity of biliary excretion mechanisms for
irinotecan, CPT-11, and its metabolites in rats. Cancer Res 57: 1934-1938.
418. Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, Weizer V, Dabbs JE, Froehlich
R, Green CE, Sugiyama Y. 1998. Biliary excretion mechanism of CPT-11 and its metabo-
lites in humans: involvement of primary active transporters. Cancer Res 58: 5137-5143.
419. Chu XY, Kato Y, Sugiyama Y. 1999. Possible involvement of P-glycoprotein in biliary
excretion of CPT-11 in rats. Short communication. Drug Metab Dispos 4: 440-441.
420. Horikawa M, Kato Y, Sugiyama Y. 2002. Reduced gastrointestinal toxicity following
inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.
Pharm Res 19: 1345-1353.
421. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, Baer
MR. 2005. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin
Cancer Res 11: 2320-2326.
422. Arimori K, Kuroki N, Hidaka M, Iwakiri T, Yamsaki K, Okumura M, Ono H, Takamura
N, Kikuchi M, Nakano M. 2003. Effect of P-glycoprotein modulator, cyclosporin A, on
the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res
20: 910-917.
423. Gupta E, Safa AR, Wang X, Ratain MJ. 1996. Pharmacokinetic modulation of irinotecan
and metabolites by cyclosporin A. Cancer Res 56: 1309-1314.
424. Chester JD, Joel SP, Cheeseman SL, Hall GD, Braun MS, Perry J, Davis T, Button CJ,
Seymour MT. 2003. Phase I and pharmacokinetic study of intravenous irinotecan plus
oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. J Clin
Oncol 21: 1125-1132.
425. Innocenti F, Undevia SD, Ramirez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M,
Ratain MJ. 2004. A phase I trial of pharmacologic modulation of irinotecan with
cyclosporine and phenobarbital. Clin Pharmacol Ther 76: 490-502.
426. Oguchi H, Miyasaka M, Koiwai T, Tokunaga S, Hora K, Sato K, Yoshie T, Shioya H,
Furuta S. 1993. Pharmacokinetics of temocapril and enalapril in patients with various
degrees of renal insufficiency. Clin Pharmacokinet 24: 421-427.
427. Nakashima M, Yamamoto J, Shibata M, Uematsu T, Shinjo H, Akahori T, Shioya H,
Sugiyama K, Kawahara Y. 1992. Pharmacokinetics of temocapril hydrochloride, a novel
angiotensin converting enzyme inhibitor, in renal insufficiency. Eur J Clin Pharmacol
43: 657-659.
428. Hoyer J, Schulte KL, Lenz T. 1993. Clinical pharmacokinetics of angiotensin converting
enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet 24: 230-254.
429. Puchler K, Eckl KM, Fritsche L, Renneisen K, Neumayer HH, Sierakowski B, Lavrijssen
AT, Thomsen T, Roots I. 1997. Pharmacokinetics of temocapril and temocaprilat after
14 once daily oral doses of temocapril in hypertensive patients with varying degrees of
renal impairment. Br J Clin Pharmacol 44: 531-536.
430. Ishizuka H, Konno K, Naganuma H, Sasahara K, Kawahara Y, Niinuma K, Suzuki H,
Sugiyama Y. 1997. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is
excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in
Eisai hyperbilirubinemic mutant rats (EHBR). J Pharmacol Exp Ther 280: 1304-1311.
431. Gotoh Y, Suzuki H, Kinoshita S, Hirohashi T, Kato Y, Sugiyama Y. 2000. In-
volvement of an organic anion transporter (canalicular multispecific organic anion
transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of
glutathione conjugates in rats. J Pharmacol Exp Ther 292: 433-439.
Search WWH ::
Custom Search